AKR1C3-negative high-risk metastatic castration-sensitive prostate cancer has long-term response to first-line treatment with abiraterone: Four case reports

Tsuyoshi Yoshizawa; Yoko Nakanishi; Daisuke Obinata; Kenya Yamaguchi; Shinobu Masuda; Satoru Takahashi

doi:10.1016/j.eucr.2024.102727

AKR1C3-negative high-risk metastatic castration-sensitive prostate cancer has long-term response to first-line treatment with abiraterone: Four case reports

Urol Case Rep. 2024 Apr 3:54:102727. doi: 10.1016/j.eucr.2024.102727. eCollection 2024 May.

Authors

Tsuyoshi Yoshizawa¹, Yoko Nakanishi², Daisuke Obinata¹, Kenya Yamaguchi¹, Shinobu Masuda², Satoru Takahashi¹

Affiliations

¹ Department of Urology, Nihon University School of Medicine, Japan.
² Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Japan.

Abstract

We experienced four cases of high-risk metastatic castration-sensitive prostate cancer (mCSPC) in which first-line treatment with abiraterone showed a sustained long-term response of over 5 years. We conducted immunohistochemical staining of aldo-keto reductase family 1 member C3 (AKR1C3) expression, which associate with poor prognosis of metastatic castration-resistant prostate cancer (mCRPC), and all prostate cancer tissue from four cases showed negative. These results suggested that AKR1C3-negative high-risk mCSPC cases may respond well to first-line treatment with abiraterone. This is the first report describing association of high-risk mCSPC and negative AKR1C3.

Keywords: Abiraterone; High-risk metastatic castration-sensitive prostate cancer; aldo‐keto reductase family 1 member C3.

Publication types

Case Reports